VA opens a nondrug path for veterans living with essential tremor
Encora Therapeutics’ Encora X1 is now available to order through the U.S. Department of Veterans Affairs, giving clinicians in that system a wearable option for adults with essential tremor who need something beyond medication. The FDA-cleared wrist device uses mechanical neurostimulation rather than electrical stimulation, a design choice that may widen access for patients who cannot tolerate standard drug therapy or who live with implanted electrical devices that complicate other approaches.
The change matters at the bedside because essential tremor is not a cosmetic nuisance. It interferes with eating, drinking, writing, and other movements that define independence, and in veterans those losses accumulate inside already complex medical regimens. When tremor forces a patient to use two hands for a cup, avoid certain foods, or ask for help pouring a drink, the condition has crossed from inconvenient to functionally disabling.
More than 30,000 veterans receiving VA care carried a recorded essential tremor diagnosis in a single year, based on a peer-reviewed national analysis of VA health records published in Tremor and Other Hyperkinetic Movements. Nationally, essential tremor affects an estimated 7.6 million people in the United States, making it one of the most common movement disorders in adult medicine. The burden is likely to be seen first in primary care, long before patients reach a movement-disorders specialist.
Mechanical neurostimulation at the wrist changes the treatment conversation
Encora X1 is worn at the wrist and is roughly the size of a smartwatch. It delivers mechanical neurostimulation to the median, radial, and ulnar peripheral nerve distributions, targeting the pathways that influence hand tremor during action. Because it is worn on demand, the device can be activated during the specific activities patients struggle with most, such as meals, handwriting, or using a phone.
The absence of electrical stimulation is clinically relevant. Patients with implanted devices such as pacemakers often face constraints when clinicians consider certain noninvasive technologies, and a wearable that avoids electrical contraindications expands the set of options available during shared decision-making. For some veterans, that may mean a nonprocedural treatment pathway where none existed before.
The device is available by prescription only, and veterans can ask their VA care team whether it fits their situation. VA facilities can purchase it through Lovell Government Services, a service-disabled veteran-owned small business certified by the Small Business Administration that is contracted to process Encora X1 orders.
One practical advantage of a wearable tremor device is the ability to match treatment intensity to daily life rather than commit to continuous systemic exposure.
Drug intolerance leaves a treatment gap that devices can partially fill
Medication remains the usual first-line treatment for essential tremor, but the pharmacologic route does not work for everyone. Side effects can be limiting, and some patients never achieve enough tremor control to regain the activities that matter most. Older adults, patients with multiple comorbidities, and those already managing large medication lists may be especially reluctant to add another chronic drug for a symptom they experience mainly during functional tasks.
That is where a nondrug wearable can sit in the care pathway. It does not replace all tremor treatment, and it does not solve the underlying disease biology, but it gives clinicians a way to treat function directly. For a patient who only needs tremor reduction while eating dinner or signing documents, on-demand use can be more useful than a therapy designed for around-the-clock suppression.
The company said the device can be used alongside medication or on its own. That flexibility is important in real-world care, where many patients already have a partial response to medication and need an add-on strategy rather than a wholesale switch.
Early clinical testing showed rapid symptom relief and high comfort
In clinical studies, device effects were observed within about 15 minutes of use. Rapid onset matters because tremor is often most disruptive in the moment a task begins, not hours later. A therapy that can be turned on near the time of need better fits the lived pattern of essential tremor than one that requires broad, chronic exposure before any functional benefit appears.
In a randomized, double-blind, sham-controlled study, 70% to 75% of participants achieved a one-point improvement in tremor-related disability during everyday tasks after 30 minutes of stimulation, compared with 48% in the sham group. The gap suggests the intervention had a measurable effect beyond expectation alone, though individual response still varied. The company also said 96% of study participants rated the therapy as “comfortable all of the time.” Comfort is not a trivial endpoint for a wrist-worn device; adherence collapses quickly when a therapy interferes with ordinary movement or becomes annoying to wear.
The study data point to a straightforward mechanism of bedside value: if a patient can keep the device on throughout the day and activate it when needed, the barrier to use drops sharply. Tremor control becomes task-specific instead of continuous and burdensome.
VA access may accelerate adoption of nondrug tremor care
Federal procurement channels can shape how quickly a therapy reaches practice. Once a device is available through the VA, clinicians inside that system have a clearer route for prescribing it, which can make a real difference in a population with high chronic disease burden and frequent medication intolerance. The availability also gives primary care physicians a concrete option to discuss before a neurology referral or in parallel with specialty care.
Essential tremor is often managed in steps: medication first, then procedures for patients with refractory or disabling symptoms. Between those poles sits a large group of patients whose tremor disrupts daily function but who are not ready for invasive intervention. A wearable mechanical device addresses that middle space directly.
For veterans, the appeal is plain. They may want to keep driving, eating out, writing, or handling a phone without drawing attention to their hands. A noninvasive device that does not require surgery, implantation, or a new drug burden gives care teams another route to preserve those routines. The central question now is not whether tremor matters—it does—but how often this wearable can restore usable hand function across the broad, medically complex veteran population that carries the diagnosis.